Chinese makers of pharmaceutical ingredients are coming under increasing scrutiny from the U.S. FDA in an effort to bolster the safety of the U.S. drug supply chain, Christopher Hickey, director of the FDA's office in China, said Thursday at a hearing in Washington. The process of adding inspectors and staff in China has started on the back of the FDA's new legal authority and additional funding, he said. "As the number of medical products coming from China has increased, so have the challenges," he told the U.S.-China Economic and Security Review Commission.

Full Story:
Reuters, Bloomberg

Related Summaries